Skip to content

CDMO Services & Technologies for Biopharmaceuticals

We provide comprehensive CDMO services for biologics and advanced therapies paired with stellar technologies to bring your candidate to clinic - on time, with top quality, and tailored to your needs.

WHO WE ARE

Your Trusted CDMO Partner

As a fully integrated CDMO, we specialize in the development and manufacturing of biopharmaceutical active ingredients, viral vectors, and vaccines.

Our expertise spans high-performance cell line development, robust process development, efficient and reliable GMP manufacturing, and outstanding analytical services for proteins & antibodies as well as viral vectors & vaccines.

Leveraging proprietary technologies, we deliver exceptional process yields while ensuring superior potency and quality for your products.

Whether working with therapeutic proteins, viral vectors, or vaccines, we are your experienced partner for seamless development and manufacturing.

>

Employees

Years of Experience

Production Sites

WHAT WE OFFER

Integrated CDMO Services

Enabling Technologies

Asset 7Proteins & Antibodies

 

 

Cell Line Development

Cell Banking

Tech Transfer

Process Development

GMP Manufacturing

Analytics & Bioassays

 

Asset 8Vaccines & Viral Vectors  
 
 

Vector Design

Production Systems

Process Development

GMP Manufacturing

Analytics & Bioassays

LV, AAV, MVA

 

Asset 10Protein & Antibody

 

 

ADCC Enhancement

Transposase System

Expression Cell Lines


 

 

 

Asset 9 Vaccines & Viral Vector

 

 

MVA Vector Platform

LV Production System

Designer Cell Line

 

 

 

 

 

WHAT WE OFFER

Integrated CDMO Services

Services Proteins Antibodies
Proteins & Antibodies 

 

 

  • Cell Line Development
  • Cell Banking  (MCBs & WCBs)
  • Process Development (USP/DSP)
  • GMP Manufacturing
  • Technology Transfer
  • Analytics & Bioassays
  • Biosimilars & Biobetters

 

Asset 5
Viral Vectors & Vaccines

 

 

  • Producer Cell Line Development
  • Process Development
  • GMP Manufacturing
  • Quality Analytics
  • AAV Production
  • Lentivirus Production
  • Poxvirus Production

 

Proprietary Technologies

Asset 3-1
Proteins & Antibodies 

 

 

  • GlymaxX® - ADCC Enhancement/
    Glycoengineering
  • DirectedLuck® - Transposase System
  • CHO.RiGHT® - Producer Cell Line

 

Asset 6
Viral Vectors & Vaccines
  

 

  • MVA-CR19 - Vector Platform
  • Lenti.RiGHT® - Production System
  • DirectedLuck® - Transposase System
  • AGE1® - Designer Cell Line

Customer Quotes

"In the midst of an escalating pandemic, ProBioGen successfully managed safety, staffing, and procurement to maintain aggressive timelines for Pionyr's two first-in-class TME-directed afucosylated monoclonal antibodies."

Logo_Icon_Customer_Quote_Pionyr_Immunotherapeutics_Inc.


SVP, Technical Operations | Pionyr Immunotherapeutics, Inc.

"Thanks to ProBioGen's continuous support and regularly provided valuable information — not only on technical challenges but also urgent issues associated with the project — our teams were able to bring a product from their facility to clinic as scheduled, within several months, here in Japan."

Logo_Icon_Customer_Quote_Chiome_Bioscience_Inc.


Director, CMC Development | Chiome Bioscience Inc.

"In ProBioGen, we see a company that values scientific contribution and enables high-quality drug development for customers, which ultimately benefits the patients we all serve."

Logo_Icon_Customer_Quote_Celgene_Corporation


Senior Director, Biologics Development | Celgene Corporation

OUR PROMISE TO YOU

Your Biologics. Elevated.®

Success
 
German Quality
  • Scientific expertise in everything we do
  • Proprietary technologies for a superior outcome
  • More than 70% of satisfied customers seen in repeat business

 

Asset 18
 
Proven Flexibility
  • Our experienced CMC managers interfacing with clients on individual needs
  • Customized and modular approach allows for outstanding flexibility
  • Our proprietary technologies also ensure this flexibility
Time is Money

Fast Timelines
  • One-stop-shop with integrated services and technologies
  • Early risk mitigation strategies
  • Parallel project starts with multiple molecules possible

 

Elevate Your Candidate With The Right CDMO

Latest News

ProBioGen Expands Protein and Viral Manufacturing to Drive Continued Growth

Jan 7, 2025

Transgene and ProBioGen Join Forces to Advance Individualized Cancer Vaccine Development

Nov 5, 2024

ModeX Therapeutics Leverages ProBioGen's Expertise for Accelerated COVID-19 Antibody Development

May 29, 2024

Upcoming events

Biologics Manufacturing Germany

Munich, Germany
Booth #5
Visit event website 


CAR-TCR Summit Europe

25th-27th February


DG-GT 2025 Annual Meeting

Visit our Booth
Visit event website 


BIO-EUROPE Spring


Visit event website 

ProBioGen AG

Headquarters

Herbert-Bayer-Straße 8

13086 Berlin, Germany

Phone: +49 (0) 30 3229 35 100

Email: info@probiogen.de

Newsletter
Join for ProBioGen News - make sure to be always up-to-date and fully informed with our latest company announcements.